Strategic Acquisition La Jolla is now a subsidiary of Innoviva after a $149M acquisition, indicating a potential alignment with Innoviva’s broader portfolio and sales channels. Explore cross-sell opportunities for XERAVA and GIAPREZA through Innoviva’s commercial footprint and partner networks.

Portfolio Fit Existing marketed therapies include GIAPREZA (angiotensin II) and XERAVA (eravacycline) for serious infections. Position complementary anti-infective and hemodynamic support solutions to hospital systems seeking integrated care for high-acuity patients.

Clinical Leadership New leadership additions such as a Chief Medical Officer and the company’s focus on life-threatening diseases suggest a priority on translational and clinical education. Target Key Opinion Leaders and hospital medical affairs for clinical advocacy and payer evidence generation.

Regulatory and Legal Recent litigation and fiduciary scrutiny around the acquisition signal heightened diligence among investors and buyers. Leverage this by offering transparent value demonstrations, robust post-merger integration plans, and risk-mitigated contracting terms to healthcare facilities and distributors.

Market Growth Revenue range indicates mid-market scale with room to grow in specialty infectious disease and critical care markets. Identify opportunities with ID/Hospital networks, GPOs, and biopharma partners seeking to expand portfolio reach in niche therapies and lifecycle management.